Department of Cardiology, Hartford Hospital, Hartford, CT; Department of Kinesiology, University of Connecticut, Storrs, CT.
Department of Psychiatry, Yale University, New Haven, CT; Olin Neuropsychiatry Center, Institute of Living, Hartford Hospital, Hartford, CT.
Am Heart J. 2018 Mar;197:166-174. doi: 10.1016/j.ahj.2017.10.027. Epub 2017 Dec 6.
Functional magnetic resonance imaging (fMRI) has not been used to assess the effects of statins on the brain. We assessed the effect of statins on cognition using standard neuropsychological assessments and brain neural activation with fMRI on two tasks.
Healthy statin-naïve men and women (48±15 years) were randomized to 80 mg/day atorvastatin (n=66; 27 men) or placebo (n=84; 48 men) for 6 months. Participants completed cognitive testing while on study drug and 2 months after treatment cessation using alternative test and task versions.
There were few changes in standard neuropsychological tests with drug treatment (all P>.56). Total and delayed recall from the Hopkins Verbal Learning Test-Revised increased in both groups (P<.05). The Stroop Color-Word score increased (P<.01) and the 18-Point Clock Test decreased in the placebo group (P=.02) after drug cessation. There were, however, small but significant group-time interactions for each fMRI task: participants on placebo had greater activation in the right putamen/dorsal striatum during the maintenance phase of the Sternberg task while on placebo but the effect was reversed after drug washout (P<.001). Participants on atorvastatin had greater activation in the bilateral precuneus during the encoding phase of the Figural Memory task while on-drug but the effect was reversed after drug washout (P<.001).
Six months of high dose atorvastatin therapy is not associated with measurable changes in neuropsychological test scores, but did evoke transient differences in brain activation patterns. Larger, longer-term clinical trials are necessary to confirm these findings and evaluate their clinical implications.
功能磁共振成像(fMRI)尚未用于评估他汀类药物对大脑的影响。我们使用标准神经心理学评估和 fMRI 对两项任务评估了他汀类药物对认知的影响。
健康的他汀类药物初治男性和女性(48±15 岁)随机分为每天 80mg 阿托伐他汀(n=66;27 名男性)或安慰剂(n=84;48 名男性)治疗 6 个月。参与者在研究药物治疗期间和停药后 2 个月使用替代测试和任务版本完成认知测试。
药物治疗对标准神经心理学测试的变化很少(所有 P>.56)。Hopkins 言语学习测试修订版的总回忆和延迟回忆在两组中均增加(P<.05)。停药后,Stroop 颜色词测试得分增加(P<.01),18 点时钟测试得分降低(P=.02)。然而,每个 fMRI 任务都存在较小但显著的组间时间交互作用:安慰剂组在 Sternberg 任务的维持阶段,在服用安慰剂时右壳核/背侧纹状体的激活增加,但停药后效果逆转(P<.001)。阿托伐他汀组在 Figural Memory 任务的编码阶段药物治疗时双侧楔前叶的激活增加,但停药后效果逆转(P<.001)。
6 个月的高剂量阿托伐他汀治疗与神经心理学测试分数的可测量变化无关,但确实引起了大脑激活模式的短暂差异。需要更大、更长时间的临床试验来证实这些发现并评估其临床意义。